SAM-DNMT3A, a strategy for induction of genome-wide DNA methylation, identifies DNA methylation as a vulnerability in ER-positive breast cancers

Nat Commun. 2024 Dec 1;15(1):10449. doi: 10.1038/s41467-024-54824-8.

Abstract

DNA methylation is an epigenetic mark that plays a critical role in regulating gene expression. DNA methyltransferase (DNMT) inhibitors, inhibit global DNA methylation and have been a key tool in studies of DNA methylation. A major bottleneck is the lack of tools to induce global DNA methylation. Here, we engineered a CRISPR based approach, that we initially designed, to enable site-specific DNA methylation. Using the synergistic activation mediator (SAM) system, we unexpectedly find that regardless of the targeted sequence any sgRNA induces global genome-wide DNA methylation. We term this method SAM-DNMT3A and show that induction of global DNA methylation is a unique vulnerability in ER-positive breast cancer suggesting a therapeutic approach. Our findings highlight the need of caution when using CRISPR based approaches for inducing DNA methylation and demonstrate a method for global induction of DNA methylation.

MeSH terms

  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / genetics
  • Breast Neoplasms* / metabolism
  • CRISPR-Cas Systems
  • Cell Line, Tumor
  • DNA (Cytosine-5-)-Methyltransferases* / genetics
  • DNA (Cytosine-5-)-Methyltransferases* / metabolism
  • DNA Methylation*
  • DNA Methyltransferase 3A* / metabolism
  • Epigenesis, Genetic
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • MCF-7 Cells
  • RNA, Guide, CRISPR-Cas Systems / genetics
  • Receptors, Estrogen / genetics
  • Receptors, Estrogen / metabolism

Substances

  • DNA Methyltransferase 3A
  • DNA (Cytosine-5-)-Methyltransferases
  • DNMT3A protein, human
  • Receptors, Estrogen
  • RNA, Guide, CRISPR-Cas Systems